Related Experiment Videos
Salvage treatment with apatinib for advanced non-small-cell lung cancer
Zhengbo Song1, Xinmin Yu1, Guangyuan Lou1
1Department of Chemotherapy, Zhejiang Cancer Hospital; Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Zhejiang province, Hangzhou, People's Republic of China.
Objective:
No definitive chemotherapeutic regimen has been established in patients with non-small-cell lung cancer (NSCLC) who failed second- or third-line treatment. The aim of this study was to evaluate apatinib, a VEGFR-2 inhibitor, in advanced NSCLC as salvage treatment.
Methods:
We evaluated the efficacy and toxicity of apatinib in patients with previously treated advanced NSCLC from 2014 to 2015 in Zhejiang Cancer Hospital. Survival analysis was performed by the Kaplan-Meier method.
Results:
Forty-two patients were included in the present study. Four patients achieved partial response, and 22 achieved stable disease, representing a response rate of 9.5% and a disease control rate of 61.9%. Median progression-free survival and overall survival were 4.2 and 6.0 months, respectively. The toxicities associated with apatinib were generally acceptable with a total grade 3/4 toxicity of 50%.
Conclusion:
Apatinib appears to have some activity against advanced NSCLC when utilized as salvage treatment.
Insights
Apatinib showed activity in advanced non-small-cell lung cancer (NSCLC) patients who failed prior treatments. This salvage therapy demonstrated a disease control rate of 61.9% with manageable toxicity.
Area of Science:
- Oncology
- Pharmacology
Background:
- Establishing a definitive chemotherapeutic regimen for advanced non-small-cell lung cancer (NSCLC) after second- or third-line treatment remains a challenge.
- VEGFR-2 inhibitors represent a potential therapeutic avenue for refractory NSCLC.
Purpose of the Study:
- To evaluate the efficacy and toxicity of apatinib as a salvage treatment in advanced NSCLC patients.
- To assess the response rate, disease control rate, progression-free survival, and overall survival of apatinib in this patient population.
Main Methods:
- A prospective study was conducted with 42 advanced NSCLC patients who had previously undergone treatment.
- Efficacy and toxicity of apatinib were assessed, with survival analysis performed using the Kaplan-Meier method.
Main Results:
- Apatinib achieved a partial response in 9.5% of patients and stable disease in 52.4%, resulting in a disease control rate of 61.9%.
- Median progression-free survival was 4.2 months, and median overall survival was 6.0 months.
- Grade 3/4 toxicity was observed in 50% of patients, indicating generally acceptable tolerability.
Conclusions:
- Apatinib demonstrates notable activity as a salvage treatment for advanced NSCLC.
- The drug offers a potential treatment option for patients with limited therapeutic choices after failure of standard therapies.